Urinary Tumor Markers for Bladder Cancer AHS - G2125
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Clinical coverage guidance on the use of urinary tumor marker tests for detection and surveillance of bladder cancer for Blue Cross Blue Shield - North Carolina providers and members.
CPT codes 0613U was added to the Billing/Coding section effective 1/1/2026.
CPT codes 0012M, 0013M, 0363U, 0420U, 0452U, 0465U, 0549U, and 0613U were removed from this policy and will be managed under policy Liquid Biopsy AHS - G2054.
EAU and other guideline positions updated to reflect 2022–2024 guidance that urinary molecular marker tests cannot replace cystoscopy in routine practice, but some tests may approach cystoscopy sensitivity for high-grade disease and could be used to replace and/or postpone cystoscopy in selected surveillance situations.
Coverage Criteria for Urinary Tumor Markers
General coverage posture
Covered when aligned with accepted diagnostic/surveillance pathways and evidence:
Biomarkers are adjunctive and do not replace cystoscopy
Use of urinary biomarkers
Biomarker use and limitations (evidence summary):
Evidence is heterogeneous; many tests show higher sensitivity but lower specificity than cytology
Lower disease prevalence reduces positive predictive value; clinical guidelines do not support routine screening
Test performance considerations
Performance varies by test and tumor grade/stage:
Reported sensitivity/specificity values vary widely across studies and by assay (e.g., cystoscopy sensitivity 0.71–0.92; cytology sensitivity low particularly for grade 1–2)
Covered Indications
Covered when ONE of the following is met:
From policy 'When Urinary Tumor Markers for Bladder Cancer is covered'
From policy 'When Urinary Tumor Markers for Bladder Cancer is covered'
From policy 'When Urinary Tumor Markers for Bladder Cancer is covered'
When Covered / Policy summary
Policy coverage stance and historical notes
Reflects policy implementation and update history language clarifying that reimbursement is allowed when criteria/guidelines are met.
Coverage criteria stability
Current coverage limits
Coverage criteria have remained stable through documented reviews; coding additions were administrative and did not alter coverage logic.
Urinary tumor biomarkers should not be used as a replacement for cystoscopy for initial diagnosis or routine screening of asymptomatic populations. Cystoscopy (white light) with urine cytology remains the diagnostic gold standard, and while some biomarkers may increase sensitivity when combined with cytology, overall test performance is heterogeneous and generally inferior to cystoscopy—particularly for low‑grade or low‑stage tumors.
Reimbursement is not allowed for urinary biomarkers—including bladder tumor antigen (BTA), nuclear matrix protein 22 (NMP22), and UroVysion FISH—when used for screening of bladder cancer in asymptomatic individuals, for the evaluation of hematuria, for diagnosing bladder cancer in symptomatic individuals, or for any other non‑specified indications.
Reimbursement is not allowed for ImmunoCyt / uCyt when used for the evaluation of hematuria, for diagnosing bladder cancer in symptomatic individuals, or for population screening of asymptomatic persons. Although ImmunoCyt may be used as an adjunctive tool in specific monitoring contexts, it is excluded from coverage for these diagnostic or screening indications.
Any other urinary tumor markers for bladder cancer that are not explicitly mentioned in this policy do not meet coverage criteria and are not reimbursed when used for non‑covered indications. Evidence for many proprietary or laboratory‑developed urine tests remains limited and overall clinical utility has not been established to replace standard diagnostic pathways.
Historically, BCBSNC originally stated coverage was provided only when medical criteria were met and at times explicitly excluded reimbursement for “all other urinary biomarkers” (including but not limited to quantitative mRNA tests such as CxBladder). Over subsequent reviews the policy language was revised: the phrasing that labeled all other urinary biomarkers as investigational was removed in the 5/17/22 update, and the policy now indicates reimbursement is allowed when the documented medical criteria or reimbursement guidelines are met.
Routine use of urinary biomarkers for population screening or as a standalone replacement for cystoscopy and cytology is not supported. Biomarkers may be considered as adjuncts in defined clinical situations (for example, to help evaluate atypical or equivocal cytology results or to monitor selected high‑risk non–muscle‑invasive bladder cancer patients), but they are not recommended for routine population screening or as a primary substitute for cystoscopy.
Use of urinary tumor markers for indications outside the listed adjunctive, medically‑necessary uses (for example, routine screening of asymptomatic individuals, primary diagnosis in symptomatic patients, or evaluation of hematuria) is considered not covered. Providers should document clinical rationale and prior cystoscopy/cytology results when ordering biomarkers for allowed adjunctive indications.
The policy wording was updated on 5/17/22 to remove prior language that labeled certain urinary biomarkers as investigational and not reimbursed. This change clarified that reimbursement is determined by whether the specific medical criteria and reimbursement guidelines are met rather than an absolute investigational designation for all other biomarkers.
Billing and Coding
| Xpert® BC Monitor | Proprietary molecular test measuring five target mRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) used for surveillance of NMIBC |
| NMP22 | Nuclear matrix protein 22 quantitative/qualitative assays (FDA-approved) |
| BTA (BTA stat®, BTA TRAK®) | Bladder tumor antigen tests detecting complement factor H-related protein |
| UroVysion | FISH assay detecting chromosomal alterations (chromosomes 3,7,17 and 9p21) |
| ImmunoCyt / uCyt+ | Fluorescent immunocytology detecting glycoproteins expressed on cancerous cells |
| Bladder CARE™ | Laboratory-developed DNA methylation urine test (Pangea) — not FDA approved |
| Bladder EpiCheck | 15-marker DNA methylation urine test (Nucleix) — not available in US |
| UBC® Rapid | Point-of-care test measuring soluble cytokeratin 8/18 fragments |
| Oncuria™ | Multiplex immunoassay detecting ten protein biomarkers in urine |
| URO17 | Assay detecting keratin 17 for bladder/urogenital cancer |
| BTA stat | Bard BTA stat Test (FDA approved 1997) |
| BTA TRAK | Bard BTA TRAK Test (FDA approved 1998) |
| NMP22 Test Kit / BladderChek | MATRITECH NMP22 Test Kit / NMP22 BladderChek (FDA approvals 1996, 2002) |
| UroVysion | UroVysion Bladder Cancer Kit (FISH) (FDA approved 2005) |
| ImmunoCyt | ImmunoCyt direct immunofluorescence assay (FDA approved 2000) |
Provider Actions, Documentation, and Prior Authorization
Prior authorization may be required for proprietary urine biomarker tests
Some proprietary and multi-marker urine tests (for example, Xpert® Bladder Cancer Monitor and other commercial assays) are intended for surveillance or specific diagnostic contexts and may require prior authorization per payer rules when used as an alternative to standard cystoscopy‑based evaluation.
- Prior authorization may be required when proprietary urine biomarker tests are used in place of cystoscopy-based evaluation or for surveillance of NMIBC.
Medical criteria required for reimbursement
Reimbursement is conditional on meeting the policy's medical criteria: urinary biomarkers (BTA, NMP22, UroVysion FISH) are covered only as adjuncts for atypical/equivocal cytology or for monitoring high‑risk non‑muscle‑invasive bladder cancer; ImmunoCyt/uCyt is allowed as an adjunct to cystoscopy or cytology in monitoring.
- Provider must document that the test is being used as an adjunct for atypical/equivocal cytology or for monitoring high‑risk NMIBC to qualify for reimbursement.
Applicable codes may require review
Codes listed in the Billing/Coding section (e.g., 86294, 86316, 86386, 88120, 88121, 88346, 88350, 0365U–0367U) are included for provider reference but their presence does not guarantee payment; they may be subject to medical necessity review.
- Inclusion of a code in the policy's coding list does not guarantee reimbursement.
- BCBSNC may perform medical necessity review on claims associated with these codes.
Cystoscopy remains the gold standard
Cystoscopy (white light) with urine cytology remains the gold‑standard diagnostic and surveillance modality for bladder cancer; urinary biomarkers are described as adjuncts and should not replace cystoscopy for initial diagnosis or routine surveillance.
- Cystoscopy is the procedure of choice for initial diagnosis and surveillance.
- Fluorescent cystoscopy may increase detection but has higher false positives and cost.
Use urinary markers as adjuncts to cystoscopy
Urinary biomarkers should be used as adjuncts to cystoscopy and cytology (for example, to increase sensitivity when cytology is atypical/equivocal or for surveillance of high‑risk NMIBC) and should not replace cystoscopy per guideline and policy statements.
- Do not use urine markers as a standalone replacement for cystoscopy.
- Use biomarkers to supplement cystoscopy/cytology in specified scenarios (atypical cytology, high‑risk NMIBC monitoring).
Provider action — see policy criteria and documentation
Reserve: provider actions impacting authorization, coding, or coverage decisions should follow the policy criteria and documentation requirements described below.
Document rationale when ordering urinary biomarker tests
Providers should document the clinical rationale when ordering urinary biomarker tests, including the clinical context (e.g., surveillance vs. hematuria evaluation), prior cystoscopy and cytology results when applicable, and indication aligning with covered uses.
- Include prior cystoscopy and cytology findings when relevant.
- Specify whether the test is being used as an adjunct for atypical/equivocal cytology or for monitoring high‑risk NMIBC.
Coverage requires documentation of medical criteria
Reimbursement is allowed only when the medical criteria are met: tests must be used as adjuncts for atypical/equivocal cytology or for monitoring high‑risk NMIBC (and ImmunoCyt/uCyt only as an adjunct to cystoscopy or cytology).
- Claims must demonstrate the indication meets the policy's covered uses to be eligible for reimbursement.
BCBSNC may request records; letters alone often insufficient
BCBSNC may request medical records to determine medical necessity; letters alone are not sufficient unless they include all specific information needed for the determination. Coding changes may move some tests to other policies, which can affect where documentation/authorization is submitted.
- Provide full medical records when requested; letters of support are insufficient unless they contain all required specifics.
- Some CPT codes were moved to a different policy (Liquid Biopsy AHS - G2054) which may change authorization/document submission location.
Screening with urinary biomarkers is not recommended
Use of urinary biomarkers for general population screening is not cost‑effective or recommended; biomarkers have not demonstrated adequate clinical utility to replace cystoscopy for screening.
- Do not use urinary biomarkers for population screening of bladder cancer.
Denial risk for non‑covered indications
Claims for urinary biomarkers used for screening of asymptomatic individuals, evaluation of hematuria, or diagnosing symptomatic individuals (and other non‑specified indications) will be denied as not covered.
- Do not submit claims for biomarker testing for screening, hematuria evaluation, or primary diagnosis in symptomatic patients; these indications are not allowed.
Documentation and medical necessity reviews may be required
Inclusion of codes in the Billing/Coding section does not guarantee reimbursement; BCBSNC may request medical records and perform medical necessity review to determine coverage and payment.
- Be prepared to submit complete medical records to support medical necessity when requested.
Background
Bladder cancer most commonly arises from the urothelium and frequently presents with painless hematuria. White light cystoscopy is the diagnostic gold standard; fluorescence cystoscopy can increase sensitivity but at greater cost and with lower specificity. Urinary tumor biomarkers (proteins, DNA methylation, mRNA panels, FISH, and immunocytology) have been developed as noninvasive detection and surveillance tools, but many lack sufficient validation and do not match cystoscopy performance—especially for low‑grade/low‑stage disease. Estimated U.S. incidence and mortality highlight disease burden (approximately 83,190 new cases and 16,840 deaths annually), and median age at diagnosis is about 73 years.
Definitions and Key Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.